• Acute Care
    Medicure achieved a ranking as
    A 2016 TSX Venture 50 Company
    Learn More
  • Acute Care
    Medicure Focuses On
    Acute Care
    Hospital Products
    Learn More
  • Aggrastat HDB FDA Approved
    FDA APPROVES
    Aggrastat HDB
    The high-dose bolus (HDB) dosing regimen has been added to the Aggrastat (tirofiban HCI) Prescribing Information.
    Learn More
  • Medicure Investments
    medicure is traded
    on TSX Venture (MPH)
    The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban HCI).
    Presentation
    Investor Information

Aggrastat

Aggrastat® is Medicure's leading speciality pharmaceutical product.

Aggrastat

Investor News

Latest Financial Reports Corporate Presentation

  Latest News

September 1, 2016
FDA Approves New AGGRASTAT® Product Format
August 10, 2016
Medicure Reports Second Quarter 2016 Financial Results
August 3, 2016
Medicure to Announce Q2 2016 Financial Results on August 10, 2016